Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study

This study provides Class III evidence that among patients with MS, younger age, being female individuals, having more comorbidities, receiving natalizumab, undergoing an escalating treatment strategy, or receiving treatment at a hospital were associated with being infected with COVID-19. Among patients with MS who were infected with COVID-19, a severe course was associated with increasing age and having a progressive form of MS, whereas not being on treatment or receiving an interferon beta agent was protective.

Source: Neurology Neuroimmunology and Neuroinflammation - January 19, 2022 Category: Neurology Authors: Iaffaldano, P., Lucisano, G., Manni, A., Paolicelli, D., Patti, F., Capobianco, M., Brescia Morra, V., Sola, P., Pesci, I., Lus, G., De Luca, G., Lugaresi, A., Cavalla, P., Montepietra, S., Maniscalco, G. T., Granella, F., Ragonese, P., Vianello, M., Bram Tags: Class III, COVID-19, Multiple sclerosis, Case control studies Article Source Type: research